NL-OMON21255招募中不适用
Azathioprine maintenance treatment versus infliximab maintenance treatment in Crohn’s disease patients in remission (Azorix trial)
Academic Medical Center (AMC)0 个研究点目标入组 130 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 130
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age between 18 and 80
- •2. For at least 6 months a stable dose of combination therapy with IFX and AZA or with IFX and 6MP
排除标准
- •1. Failed attempt to quit medication during combination therapy before
- •2. Abdominal abscesses, fistulas and fluid collections
研究者
相似试验
尚未招募
不适用
Azathioprine maintenance treatment versus Infliximab maintenance treatment in Crohn's disease patients in remissiochronic inflammatory bowel disease1001796910003816Crohn's diseaseNL-OMON32054Academisch Medisch Centrum128
进行中（未招募）
不适用
Azathioprine maintenance treatment versus Infliximab maintenance treatment in Crohn's disease patients in remission: a randomized multicenter trial - Azorix-trialEUCTR2008-001131-35-NLAcademic Medical Center, department of Gastroenterology and hepatology
Unknown
不适用
The Therapy Effect of Azathioprine Initial or 14 Weeks After Combined With Infliximab on CDCrohn DiseaseNCT03393247Sixth Affiliated Hospital, Sun Yat-sen University160
尚未招募
3 期
Azathioprine effect in severe asthmatic patientsIRCT20231219060463N1Ahvaz University of Medical Sciences40
进行中（未招募）
1 期
Can suppressing the immune system with azathioprine slow down the progression of Parkinson's disease?Parkinson's diseaseMedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-003089-14-GBCambridge University Hospitals NHS Foundation Trust and University of Cambridge60